Skip navigation
Watchlist Sponsored By :

As of Friday, November 20th:
The blended earnings growth rate for the S&P 500 for Q3 2009, combining actual numbers for companies that have reported, and estimates for companies yet to report declined to -13.8% from -13.7% in the previous day. As of October 1st, the earnings growth rate was at -24.7%.Of the 480 S&P 500 companies who have reported Q3, 79% beat estimates, 7% were in-line, and 14% were below estimates.  The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -13.8%. (Data provided by Thomson Reuters)

LATEST EARNINGS RESULTS


Current DateTime: 09:41:30 23 Nov 2009
LinksList Documentid: 29017166
Expiration DateTime: 11/23/2009 9:42:26 AM

Current DateTime: 09:41:31 23 Nov 2009
LinksList Documentid: 24355697
  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Fashion Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

  • Wines for the Holidays

      Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES


Current DateTime: 09:41:31 23 Nov 2009
LinksList Documentid: 33793611
  • How Much Do You Know About Green?

      Green has become part of our everyday lives. Green is everywhere-- energy, clothing, food, housing, transportation. It's a big business and a global business.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?


Current DateTime: 09:41:31 23 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Genentech Profit Rises but Main Drug Sales Fall Short
By: CNBC.com with Wires | 14 Jan 2008 | 04:25 PM ET
Text Size

Genetech Earnings Fourth Quarter
AP
The Genentech campus is seen in South San Francisco, Calif.

Genentech reported a profit that rose 6.4 percent and beat forecasts, but sales of all four of the company's main drugs fell short of expectations.

On an adjusted basis, the biotechnology firm said it earned $737 million, or 69 cents a share in the fourth quarter, up from $659 million, or 61 cents a share in the same period last year.

Sales at Genentech rose to $2.97 billion, compared with $2.71 billion last year.

Shares of the company lost more than 2 percent in extended trading. The stock [DNA  Loading...      ()   ] closed at $70.64 Monday, a decline of 1.2 percent.

For full-year 2008, the company expects earnings per share of $3.30 to $3.45, compared with the $3.38 per share forecast by Wall Street analysts.

Increased sales of Genentech's Avastin cancer medicine more than offset a decline in its Lucentis treatment for the leading cause of adult blindness, but revenue from all of the company's major drugs fell short of what analysts expected.

"Every single product relative to Street consensus was light. When you've got the biggest products that are the biggest growth drivers -- Avastin and Lucentis -- light, that's disappointing," said Analyst Mike King of Rodman & Renshaw.

"It's not the economy -- it's just a company that has to figure out how to reinvigorate growth, and unfortunately that is not part of the picture, at least for the first half of '08," he said

Quarterly U.S. sales of the colon-cancer and lung-cancer drug, Avastin, which most analysts view as the key barometer of Genentech's fortunes, rose 23 percent to $603 million, but still fell short of Wall Street expectations for sales near $616 million.

The U.S. Food and Drug Administration is expected to decide by late next month whether Avastin will also be approved to treat advanced breast cancer, but an advisory panel to the agency recommended in December that the application be turned down.

Genentech's fourth-quarter revenue rose 9 percent to $2.96 billion, which was in line the $2.96 billion expected by Wall Street. U.S. product sales rose 7 percent to $2.2 billion.

Domestic sales of non-Hodgkin's lymphoma drug Rituxan rose 6 percent to $596 million, while U.S. sales of breast cancer treatment Herceptin rose 2 percent to $327 million.

Sales of eye-disease medicine Lucentis fell 9 percent to $197 million.

Swiss drugmaker Roche Holding, which owns a majority stake in Genentech, records sales of Genentech drugs outside the United States.

-- Reuters contributed to this report.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon

Current DateTime: 09:41:32 23 Nov 2009
LinksList Documentid: 29016957
Expiration DateTime: 11/23/2009 9:42:57 AM

Current DateTime: 09:41:32 23 Nov 2009
LinksList Documentid: 29017287
Expiration DateTime: 11/23/2009 9:42:27 AM


Current DateTime: 06:27:23 23 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 06:27:23 23 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 06:27:23 23 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 09:12:15 23 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters